25 May 2013
Keywords: fda, fast-tracks, wyeth/, progenics, gi, drug, major
Article | 24 July 2006
Drug major Wyeth Pharmaceuticals and fellow USA-based Progenics say that their co-developed intravenous form of methylnaltrexone, being
investigated for the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
24 July 2006
24 May 2013
© 2013 thepharmaletter.com